GeneDx Holdings Corp. is a genomics and biotechnology company that provides advanced genetic testing, clinical interpretation, and genomic data solutions for rare and inherited conditions. Founded in 2000, the company offers ExomeDx and GenomeDx tests, which utilize next-generation sequencing for exome and whole genome analysis. Its proprietary GeneDx Infinity dataset supports variant interpretation and fuels discovery for biopharma partners. The company serves healthcare providers, including geneticists, pediatricians, and specialists in neonatal and pediatric critical care, as well as patients and families. GeneDx also provides research and education programs and integrates with electronic health records such as Epic Aura. The company acquired Legacy GeneDx in 2022 and Fabric Genomics in 2025. It applies artificial intelligence and machine learning tools, including the Multiscore gene ranker, to enhance diagnostic speed and accuracy. GeneDx supports clinical areas such as global developmental delay, intellectual disability, inborn errors of immunity, and neurodevelopmental disorders.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Diagnostics & Research Homepage genedx.com
Sector Healthcare IR page ir.genedx.com
Tags
genomic testing, rare disease diagnosis, exome sequencing, genome sequencing, variant interpretation, biopharma discovery, clinical genomics, pediatric genetics, newborn screening, ai-driven diagnostics, ExomeDx, GenomeDx, GeneDx Infinity, Multiscore, Fabric Genomics, Legacy GeneDx, Legacy Sema4, Epic Aura
Press page —

Metrics

Valuation  
Market cap $ 2.166B
Market cap (USD) $ 2.166B
P/E -19.23
PEG —
P/BV 8.85
P/S 4.70
P/OCF -28.85
P/FCF 151.85
Dividend yield —
Turnover / mcap —
Returns  
ROE -7.6%
ROI -5.8%
ROIC -2.7%
Profit margin -4.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 59.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 47
Quality score -16.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 427.539M 305.45M 202.566M 234.694M 212.195M 179.322M
Net profit -21.021M -52.286M -175.767M -548.98M -245.39M -241.34M
Free cash flow 14.262M -33.987M -185.397M -326.311M -199.834M -117.222M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 130.06 76.86 2.75 0.26 4.46 —
Price performance 12m 0.69 26.95 9.42 -0.94 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 32M 26.5M 42.6M — 37.4M 74.4M
↳ YoY growth -17.3% +60.8% +98.7%
↳ 5y CAGR +18.3%
Borrowings, current (USD) — — 1.77M 0.00 4.75M 497,000 1.21M 4.54M
Borrowings, non-current (USD) — — 19M 11M 6.25M 52.7M 51.9M 48.2M
Lease liabilities (USD) — — — 21.8M 66.1M 66.6M 64.3M 60.5M
Cash and deposits (USD) 1.18M 115M 1.09M 401M 124M 99.7M 85.2M 105M
Intangible assets (USD) — — — 0.00 187M 173M 159M 168M
Right-of-use assets (USD) — — — 0.00 32.8M 26.9M 25.6M 23.4M
Net debt (borrowings + leases - cash) (USD) — — -89.2M -390M -46.8M 20.1M 32.2M 8.17M
Cash flow detail
Operating cash flow (USD) — -18.7M -93.1M -190M -319M -180M -28.5M 33.3M
Purchases of property, plant and equipment (USD) — -11.9M -24.1M -9.4M -7.16M -5.25M -5.49M -19M
Change in receivables (cash effect) (USD) — -4.57M -10.6M 5.54M 5.53M 10.3M -5.42M -36.2M
Change in inventories (cash effect) (USD) — -7.97M -8.98M -10.6M 2.35M 975,000 -2.59M -3.44M
Change in payables (cash effect) (USD) — 12.8M 14.8M 25.9M 34.5M -47M -20.5M 12.1M
Interest paid (cash effect) (USD) — -305,000 -1.75M -2.75M -1.93M -3.04M -6.68M -6.41M
Income taxes paid (cash effect) (USD) — 0.00 0.00 -349,000 -1.24M -1.47M -1.17M -661,000
Share-based compensation (USD) — 5.48M 120M 219M 42M -326,000 9.14M 32.2M
Operating cash flow before change in receivables (USD) — -14.2M -82.5M -196M -325M -190M -23.1M 69.5M
Free cash flow (OCF - PPE - intangibles) (USD) — -30.7M -117M -200M -326M -185M -34M 14.3M
Income detail
Research and development expense (USD) — 34.9M 72.7M 105M 86.2M 58.3M 45.7M 72M
↳ 5y CAGR +5.5% -0.2%
Total comprehensive income (USD) — -29.7M -241M -245M -549M -175M -51.9M -20.9M
Comprehensive income to owners (USD) — -29.7M -241M -245M -549M -175M -51.9M -20.9M
Provision for credit losses (USD) — — 200,000 0.00 0.00 0.00 400,000 500,000
Credit cost ratio (credit losses / average receivables) (%) — — — 0.0% 0.0% — — 0.9%
Reported Mar 14, 2022 Mar 14, 2022 Mar 14, 2022 Aug 15, 2022 Mar 16, 2023 Feb 23, 2024 Apr 30, 2025 Feb 23, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

GeneDx Announces Leadership Transition Bull 3 Bear 0 Management

Everett Cunningham, veteran diagnostics and commercial leader, appointed Chief Executive Officer to lead next phase of growth

Katherine Stueland announces her departure from the company after successful transformation of GeneDx

GAITHERSBURG, Md – November 18, 2026 – GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that its Board of Directors has appointed Everett Cunningham as Chief Executive Officer and a member of the Board, effective on or before December 15, 2026. Mr. Cunningham succeeds Katherine Stueland, who has announced that she will step down as Chief Executive Officer and as a member of the Board when Mr. Cunningham joins GeneDx. Ms. Stueland will remain with GeneDx in an advisory capacity through January 31, 2027 to support a smooth transition.

Mr. Cunningham joins GeneDx from Quanterix Corporation, where he most recently served as President and Chief Executive Officer.

GeneDx Reports Third Quarter 2026 Financial Results Bull 4 Bear 3 Results

•Reported third quarter 2026 revenue of $123.1 million, including $110.4 million in exome and genome revenue

•Reported exome and genome volume growth of 25% year-over-year with accession growth of 28% year-over-year

•Expanded adjusted gross margin(1) to 72% and adjusted net income(1) to $8.6 million

•Reiterating full year 2026 revenue guidance of $475 to $490 million

•Hosting conference call today at 4:30 p.m. ET

GAITHERSBURG, Md., November 9, 2026 — GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the third quarter of 2026.

“Our Q3 results reflect profitable execution in a growing market, as we translate the rising demand for exome and genome testing into durable revenue growth,” said Katherine Stueland, CEO of GeneDx. “Our priorities are clear: improve the economics of our testing, expand utilization, and deliver leading products at scale.

November 5, 2026

PDF Version

Collaboration provides no-cost exome testing for eligible patients with unexplained cholestasis, early-onset cataracts, or suspected or confirmed PBD-ZSD

GAITHERSBURG, Md.--(BUSINESS WIRE)--Nov. 5, 2026-- GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a collaboration with Mirum Pharmaceuticals to offer no-cost exome testing for eligible patients across three sponsored testing programs: cholestasis, early-onset cataracts, and peroxisomal biogenesis disorder–Zellweger spectrum disorders (PBD-ZSD). Across these programs and for patients that meet specific criteria, GeneDx and Mirum are addressing a shared challenge in rare disease care: helping identify the genetic cause of symptoms that may be unexplained, affect multiple organ systems, or overlap with other conditions. Together, the programs aim to uncover underlying genetic conditions to inform diagnosis, clinical management, and treatment decisions.

Identifying the underlying genetic cause can have important implications for patient care. Certain inherited liver diseases1 can progress to liver failure, early-onset cataracts may signal genetic conditions affecting more than vision, and PBD-ZSD2 can cause progressive neurological, hearing, vision, and liver complications. Together, these programs aim to help clinicians identify underlying genetic conditions earlier and inform the diagnostic journey, clinical management and treatment decisions.

“Reaching a genetic diagnosis can be an important turning point for patients and families living with rare disease,” said Peter Radovich, President and Chief Operating Officer of Mirum Pharmaceuticals. “GeneDx’s advanced testing and deep rare disease expertise complement Mirum’s commitment to supporting patients throughout their journey by providing information that may support clinical decision-making.”

Eligible patients will receive GeneDx’s ExomeDx™ testing, with proband, duo, or trio testing options available through the programs. Clinicians will receive a comprehensive clinical report with expert interpretation of the results, and GeneDx will also offer post-test genetic counseling to help patients and families understand their results and potential next steps.

The collaboration includes three programs with distinct eligibility criteria:

  • Cholestasis: Intended for patients with unexplained cholestasis or suspected inherited cholestatic liver disease, including those with unexplained chronic liver disease, certain associated clinical findings, or a family history of genetically confirmed cholestasis. Relevant conditions may include suspected cholestatic liver diseases such as Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC). Patients with suspected extrahepatic causes or total parenteral nutrition–associated cholestasis as the primary diagnosis are excluded.

  • Early-onset cataracts: Eligible for patients ages 2 to 35 with current or previous idiopathic cataracts not attributable to infection, trauma, or other non-genetic causes.

  • PBD-ZSD: Intended for patients with diagnosed or clinically suspected peroxisome biogenesis disorder-Zellweger spectrum disorders (PBD-ZSD), a group of rare inherited metabolic disorders caused by variants in PEX genes, including patients experiencing neurological, vision, hearing, or liver deterioration.

“Rare genetic conditions can affect multiple organ systems and look remarkably different from one patient to the next, making timely diagnosis especially challenging,” said Lisa Gurry, Chief Business Officer, GeneDx. “GeneDx helps clinicians and patients find earlier answers through advanced genetic testing, expert clinical interpretation, and the world's largest rare disease dataset. Our collaboration with Mirum builds on our commitment to breaking down barriers to genetic testing, accelerating diagnosis and empowering clinicians to make more informed care decisions for patients with rare diseases.”

Testing is fully sponsored by Mirum Pharmaceuticals, and no claim will be submitted to a patient’s insurance to reduce financial barriers to testing. Healthcare providers and families interested in learning more about eligibility and ordering can visit genedx.com/cholestasis, genedx.com/cataracts and genedx.com/pbd-zsd.

About GeneDxGeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx® tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,000 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.

Forward Looking StatementsThis press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to advance gene-disease discovery, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, and (iv) future expansion of insurance coverage for exome and genome testing. The foregoing list of factors is not exhaustive. A further list and description of risks, uncertainties and other matters can be found in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, filed with the SEC on May 4, 2026, our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, filed with the SEC on August 3, 2026 and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.

| 1. Amendola M, Squires JE. Pediatric Genetic Cholestatic Liver Disease Overview. GeneReviews®. Updated May 25, 2023. https://www.ncbi.nlm.nih.gov/books/NBK584020/ |

| 2. Steinberg SJ, Raymond GV, Braverman NE, Moser AB. Zellweger Spectrum Disorder. GeneReviews®. Updated October 29, 2020. https://www.ncbi.nlm.nih.gov/books/NBK1448/ |

View source version on businesswire.com: https://www.businesswire.com/news/home/20261105481017/en/

[email protected] [email protected]

Source: GeneDx

© 2026 GeneDx, LLC

Search Investors

5

Prompts

GeneDx Holdings Corp. (ticker WGS), listed in United States.

Company History

Date Change Detail
Jan 9, 2023 Renamed SEMA4 HOLDINGS CORP. → GENEDX HOLDINGS CORP.
Jun 2, 2021 Renamed CM LIFE SCIENCES, INC. → SEMA4 HOLDINGS CORP.
— Former tickers WGSWW

ETFs Holding GeneDx Holdings Corp.

ETF Weight in ETF Shares Market value As of
ARKG 1.62% 622,315 $ 29.429M Nov 18, 2026
FSML 1.54% 28,069 $ 1.927M Jun 30, 2026
ARKK 0.83% 2,227,488 $ 105.338M Nov 18, 2026
TSME 0.67% 101,992 $ 7.002M Jun 30, 2026
WCEO 0.53% 806 $ 52.479K Jul 31, 2026
TMED 0.36% 1,200 $ 82.38K Jun 30, 2026
SSMG 0.29% 140 $ 9,115.40 Jul 31, 2026
PSC 0.20% 66,880 $ 4.591M Jun 30, 2026
HELX 0.14% 575 $ 39.474K Jun 30, 2026
ESSC 0.11% 619 $ 40.303K Jul 31, 2026
DFAS 0.02% 111,310 $ 5.774M Nov 12, 2026
MSSM 0.01% 1,158 $ 98.21K Aug 31, 2026
DCOR 0.00% 19,418 $ 1.007M Nov 12, 2026
DFSU 0.00% 980 $ 50.833K Nov 12, 2026
DFAU 0.00% 2,772 $ 143.784K Nov 12, 2026
DFAC 0.00% 11,597 $ 601.536K Nov 12, 2026
DFUS 0.00% 2,417 $ 125.37K Nov 12, 2026